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Summary Sixty-nine primary soft tissue tumours were examined for alterations of the RB1 gene which has
previously been implicated in the genesis of retinoblastoma. In three tumours loss of both alleles of this gene
(homozygous deletion) was detected. Two of these, both leiomyosarcomas, contained a chromosomal
breakpoint within the RB1 gene, while in the third tumour, a radiation induced sarcoma, complete deletion
was observed. Using a probe that detects a polymorphic locus within the RB1 gene we found loss of only one
allele (heterozygous deletion) in 33% of soft tissue sarcomas examined, including two leiomyosarcomas, a
malignant peripheral nerve sheath tumour, a rhabdomyosarcoma and a chondrosarcoma. When taken
together our results suggest that alterations of the RB1 locus may play an important part in the pathogenesis
of soft tissue tumours and particularly in leiomyosarcomas which accounted for four of the eight RB1
alterations observed in this study.
Iii recent years recombinant DNA technology has allowed
i.solation and characterisation of some of the genes involved
in tumour induction. Through study of transforming retro-
viruses and the use of the NIH3T3 mouse fibroblast trans-
formation assay several dominantly acting oncogenes have
been identified. These require an activating event in only one
of the two alleles normally present in somatic cells to enable
them to exert their transforming effect. By contrast there is a
distinct group of recessive genes which require alterations of
both alleles before they can contribute to tumour formation.
In the latter group genetic alterations appear to result in loss
of gene function and it is presumed that these genes
normally act to suppress tumour formation. The paradigm
for the recessive oncogenes is the gene at the RB locus on
the long arm of chromosome 13, the loss of which has been
implicated in the development of retinoblastoma.
Retinoblastoma is a paediatric embryonal tumour which
may present in a familial or sporadic pattern. On the basis
of the clinical and epidemiological characteristics of this
tumour Knudson proposed a model of tumour induction
requiring two hits or mutations (Knudson, 1971). Patients
with the familial form of the disease carry one hit in the
germ line while individuals who develop the tumour in a
sporadic fashion acquire both hits by somatic mutation.
Characterisation of germline and tumour cell karyotypes led
to the suggestion that these two notional hits represent
deletion or inactivation of both alleles of a gene on the long
arm of chromosome 13 (Yunis & Ramsey, 1978; Balaban-
Malenbaum et al., 1981; Benedict et al., 1983). Recently this
gene (RB1) has been cloned as a 4.7kb cDNA (Friend et al.,
1986) and alterations in the form of deletions and point
mutations have been detected in retinoblastoma specimens
(Friend et al., 1986, 1987; Fung et al., 1987; Lee et al., 1987;
Goddard et al., 1988; Dunn et al., 1988).
The possibility that RB1 is involved in the development of
other tumour types arises from the observation that patients
with the familial form of the disease often develop second
tumours several years after treatment of their retinoblastoma
(Draper et al., 1986; Friend et al., 1987; DerKinderen et al.,
1988). These second tumours are most commonly osteo-
sarcomas of bone but also include a variety of soft tissue
tumours. Structural alterations of the RB1 gene have been
detected in osteosarcomas (Friend et al., 1986, 1987; Fung et
al., 1987) and, interestingly, in some tumour types not
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commonly associated with the retinoblastoma trait such as
breast carcinoma (T'Ang et al., 1988; Lee et al., 1988) and
small cell carcinoma of the lung (Harbour et al., 1988). In
the present study we have examined a large series of soft
tissue tumours for homozygous alterations of RB1 and in
addition have assessed the prevalence of heterozygous
deletions. Our data suggest that alterations of the RBl gene
play a role in the development of certain types of soft tissue
tumour.
Methods
Primary tumours, peripheral bloods, muscle and skin biop-
sies were obtained from branches of the Royal Marsden
Hospital, Surrey and London, and St Thomas' Hospital
London. Sarcoma cell lines were obtained from the Ameri-
can Type Culture Collection. Southern analysis of DNA
extracted from these specimens was performed on nylon
hybridisation membranes using conventional protocols
(Cooper et al., 1984). Probes were radiolabelled using
random primers (Feinberg & Vogelstein, 1983). The probes
used were the 4.7kb RB1 cDNA (divided into 0.9kb and
3.8kb fragments at an internal EcoRl site) (Fung et al.,
1987), p68RS2.0, a 2.0kb probe to the variable number of
tandem repeat (VNTR) region of the RB1 gene from Dr T.
Dryja (Wiggs et al., 1988), the g3 fingerprinting probe which
detects sequences on chromosome 7 from Cellmark Diagnos-
tics courtesy of Prof. A. Jeffreys (Wong et al., 1986) and
0.9kb Mspl fragment of the pEC plasmid acting as a probe
to the VNTR region adjacent to the c-H-ras protooncogene
on chromosome 11 (Capon et al., 1983). For cytogenetic
analysis, metaphases were Giemsa banded by conventional
methods (Gallimore & Richardson, 1973).
Results
Detection of homozygous deletions of the RBI gene
Primary soft tissue tumours and cell lines were examined by
Southern analysis using fragments derived from the 4.7kb
RBl cDNA. The smaller of these, 0.9kb in size, detects 14.5,
5.8, 1.5 and 1.2kb HindIII bands while the 3.8kb probe
detects 5.3, 4.5, 7.4, 9.4, 6.2 and 2.1kb HindIII bands on
Southern blots of normal human DNA (Figures I and 2). Of
the 69 primary tumours, three (two leiomyosarcomas and
Br. J. Cancer (1989), 60, 202-205RB1 GENE IN SOFT TISSUE TUMOURS 203
1 2 3 4 5
kb
14.5 .
5.8
1.5
1.2
9.4 --.
7.4 - t
6.2
5.3 -
4.5
2.1
Figure 1 Homozygous deletions in the RBl gene detected on
Southern blots of Hindll digested DNAs hybridised to 0.9kb (a)
and 3.8kb (b) probes derived from the 4.7kb RBl cDNA. DNAs
are from: normal human leukocytes, lanes I and 2; case I, a
leiomyosarcoma, lane 3; case II, an unclassifiable sarcoma, lane
4; case III, a leiomyosarcoma, lane 5.
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Figure 2 Schematic illustration of homozygous deletions in the
RBl gene in the cases shown in Figure 1. HindIII fragments
detected by the RBl cDNAs are ordered along the 200kb of
chromosomal DNA which contain the gene. The boxes represent-
ing the cDNA probes (not to scale) lie directly underneath
HindIII fragments which they detect. The gaps in the solid lines
representing DNAs from tumours I, II and III mark the extent
of homozygous deletions.
deletions (both in leiomyosarcomas) terminate within the
RB1 gene and extend 3' to it. In case I the breakpoint lies
between the 14.5kb and 1.2kb HindIII fragments while in
case III it lies within the 3' region of the gene. The 5' extent
of these deletions has been confirmed by using a probe to a
region just 5' to the first exon of the RB1 gene (data not
shown). Interestingly, the locations of these breakpoints
correspond to zones containing two large introns of the RBI
gene. None of the set of cell lines which included a
leiomyosarcoma, a leiomyoblastoma, two rhabdomyosarco-
mas and a desmoid tumour showed abnormalities. The
background smear and the intense band running just below
the 14.5kb band on blots probed with the 0.9kb probe is
apparently due to a GC rich region which hybridises to
sequences outside the RB1 gene (Fung et al., 1987).
Detection of heterozygous deletions of the RBI gene
Homozygous deletions detectable by Southern analysis using
the RB1 cDNA probes probably constitute a small minority
of the abnormalities in this gene. In particular alterations
such as point mutations or small deletions will not be
detectable by this approach. To investigate cases where a
small alteration on one allele may coexist with a large
deletion of the other, we have used a probe to a poly-
morphic (VNTR) region within the RB1 gene (Wiggs et al.,
1988), which allows each allele to be visualised independently
(Figure 3).
In the cases illustrated two bands, each corresponding to
one allele of the RB1 gene, are seen in germline DNA
(Figure 3, lanes 1 and 3). However, in tumours from the
respective patients (Figure 3, lanes 2 and 4) only one of these
bands is seen. Hence these cases have lost at least part of
one RB1 allele during tumour development. Only cases in
one unclassifiable case) showed abnormal band patterns
(Figure 1). In case I, a leiomyosarcoma, only the 14.5kb
band detected by the 0.9kb RB1 probe remains. In case II,
the unclassifiable tumour, the gene appears entirely deleted.
Residual signal in this tumour is due to contamination of the
specimen by a population of stromal cells estimated at
approximately 15% of the total by densitometry. In case III,
a leiomyosarcoma, the band pattern generated by the 0.9kb
probe is normal but several bands usually detected by the
3.8kb probe are absent. The nature of the deletions which
give rise to these abnormal band patterns is illustrated in
Figure 2, where the genomic HindIII fragments detected by
the RB1 probes are displayed according to their order on the
200kb of DNA spanning the RB1 gene. Two of the three
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Figure 3 Examples of the detection of heterozygous deletions of
the RBI gene. Southern blots of Rsa I digested DNAs hybridised
to p68RS2.0 which detects the VNTR region within the RBI
gene. DNAs are from: germline and tumour tissue from a case of
leiomyosarcoma, lanes 1 and 2 respectively; germline and tumour
tissue from a case of pleomorphic rhabdomyosarcoma, lanes 3
and 4 respectively. The 2.0kb size marker is indicated.204 M.R. STRATTON et al.
which two alleles are seen in germline DNA are included in
the summary of results (Table I). These analyses show that
five out of 22 cases, two leiomyosarcomas, one malignant
peripheral nerve sheath tumour (MPNST), one chondro-
sarcoma and one pleomorphic rhabdomyosarcoma, showed
loss of one allele of the RB1 gene. This level of heterozygous
loss was compared with heterozygous losses of loci on
chromosomes 11 and 7. The polymorphic region on chromo-
some 11 detected by the 900bp probe from pEC is thought
to be close to a recessive gene that may be involved in the
development of rhabdomyosarcoma (Scrable et al., 1987).
The frequency of loss of heterozygosity in this region is less
than that detected by the probe to the RB1 VNTR, although
none of the tumours showing heterozygous loss at this locus
were rhabdomyosarcomas. Loss of alleles on chromosome 7
was detected in 3/37 cases and therefore appears to be less
common than for chromosomes 11 or 13. Since no recessive
oncogene has yet been localised to this chromosome we
interpret the incidence of losses on chromosome 7 as indic-
ative of background levels. The difference between levels of
heterozygous loss at these three loci is emphasised by
excluding benign or locally recurrent lesions from the anal-
ysis. When this is taken into account, heterozygous loss of
RB1 occurs in 33% of tumours compared to 16% and 11%
for the chromosome 11 and 7 loci respectively. Two cases
shbwing heterozygous RB1 deletions also showed losses of
chromosomes 7 or 11 (a MPNST and a pleomorphic
rhabdomyosarcoma) suggesting that these tumours may have
multiple chromosomal alterations.
Clinical and cytogenetic correlations with RB1 deletions
All three patients with homozygous deletions were women
under the age of 40 years at the time of diagnosis. The
leiomyosarcomas referred to as cases I and III originated
retroperitoneally and from the uterus, respectively. Of parti-
cular interest is case II. This patient previously suffered from
Hodgkin's disease and had undergone radiotherapy to the
area in which the sarcoma subsequently arose. Cytogenetic
analysis of cells from primary cultures of this presumed
radiation-induced sarcoma revealed three abnormal cell
clones. Five cells were near-dipjoid (42-48 chromosomes), six
were near-triploid (68-74 chromosomes) and 12 were near
hexaploid (128 to > 140 chromosomes). The chromosomes of
the polyploid cells were grossly rearranged, with many
marker chromosomes, but fewer abnormalities were present
in the near-diploid cells. However, a consistent finding in all
three clones was an interstitial deletion of chromosome 13
involving bands q14-q22 (data not shown). Analysis of
chromosomes obtained from dermal fibroblast cultures
showed the patient's constitutional karyotype to be normal,
with no evidence of chromosome 13 deletion.
Discussion
The group of soft tissue tumours comprises several histo-
logically distinct entities which have in common phenotypic
features of mesenchymal cells (Enzinger & Weiss, 1988). The
prevalence of individual histological types in our series of 69
primary tumours (Table I) is similar to that reported in the
general population (Enzinger & Weiss, 1988), although it
may under-represent tumours arising during childhood. Thus
the most common diagnoses are those of malignant fibrous
histiocytoma (MFH) and liposarcoma. Examination of this
series with the RB1 cDNA probes revealed three cases in
which homozygous deletions were present. In two of the
three cases, both leiomyosarcomas, a breakpoint was found
within the gene resulting in a partial homozygous deletion
while in the remaining case (an unclassifiable sarcoma) the
gene had been completely lost.
Since alterations undetectable by Southern analysis in one
allele of the RB1 gene may coexist with large deletions of the
second allele, we have used a probe to a polymorphic
(VNTR) region within the RB1 gene to examine loss of each
allele individually. This approach has been commonly used
in the past to identify large chromosomal regions lost during
tumour development. For example, before the cloning of the
RB 1 gene, loss of heterozygosity in retinoblastomas and
osteosarcomas for genetic markers on chromosome 13 had
confirmed the importance of this region in the development
of these tumour types (Cavenee et al., 1983; Dryja et al.,
1984; Hansen et al., 1985; Benedict et al., 1987; Toguchida et
al., 1988). Thus chromosome 13 markers which are large
genetic distances away from the RB 1 gene show loss of
heterozygosity in retinoblastoma and osteosarcoma in 50-
80% of cases. By comparison, our results using the probe to
the VNTR region within the RB1 gene itself show that five
out of 22 tumours examined have heterozygous deletions of
the RB 1 gene. Even when benign tumours and locally
recurrent entities such as fibromatoses are excluded from the
analysis, the incidence of heterozygous loss is only 33%. To
account for the low incidence of heterozygous deletion, it is
conceivable that loss of the RB1 gene may be an event
confined to certain classes of soft tissue tumours. In this
regard it is worthy of note that two out of three homo-
zygous and two out of five heterozygous deletions of RB1
occurred in leiomyosarcomas. Although the numbers are
small these data provide preliminary evidence that deletion
of the RB1 gene is of particular importance in the develop-
ment of leiomyosarcoma. In a study that examined alter-
ations of the RB1 gene in several tumour types (Friend et
al., 1987) three soft tissue tumours with homozygous RB1
deletions were found. One of these was also in a leiomyo-
sarcoma, one in an MFH and the last case was unclassified.
In this series only the unclassified tumour contained a
breakpoint within the RB1 gene and heterozygous loss was
not directly examined. Leiomyosarcomas have been reported
as second tumours in patients with the familial form of
retinoblastoma, but a wide range of other soft tissue
tumours have also been described in this group (Draper et
al., 1986; DerKinderen et al., 1988).
Second tumours arising in zones of previous radiotherapy
are well recognised in patients with familial retinoblastoma
(Draper et al., 1986; DerKinderen et al., 1988). The case of
Table I Summary of homozygous and heterozygous deletions of the RB1 gene in
human soft tissue tumours
Loss of heterozygosity
RBI homozygous RB1 VNTR H-ras VNTR g3
Tumour type deletions chr. 13 chr. 11 chr. 7
MFH 0/14 0/2 1/3 1/4
Liposarcoma 0/12 0/6 0/4 0/8
Leiomyosarcoma 2/11 2/3 0/2 0/3
MPNST 0/5 1/1 1/2 1/3
Fibromatosis 0/8 0/4 0/5 0/8
Rhabdomyosarcoma 0/2 1/1 0/1 1/2
Other sarcomas 1/11 1/2 1/6 0/6
Benign tumours 0/6 0/3 0/2 0/3
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homozygous RBI deletion in a sarcoma originating from an
irradiated area is therefore of particular interest. As far as
can be ascertained this patient does not have constitutional
abnormalities of the RB1 gene, nor is Hodgkin's disease a
well recognised sequela of this condition. The karyotype of
this tumour was grossly abnormal. Three related cell popula-
tions were present, each showing progressively more complex
karyotypes with increase in ploidy. An interstitial deletion of
the long arm of a chromosome 13, including part of the
band (q14) to which the RB locus maps, was found in each
line. The presence of the deletion on chromosome 13 in the
near diploid cells indicates that this alteration may have
occurred at an early stage in tumour development and it is
therefore conceivable that loss of the RB1 gene itself resulted
from the radiation insult.
Our results provide evidence that deletion of the RB1 gene
is implicated in the pathogenesis of soft tissue tumours
although the prevalence of detectable abnormalities is less
than previously reported for retinoblastoma. Our findings
also indicate that certain subgroups within the overall
classification might be particularly susceptible to this form of
genetic change and suggest that the RB1 gene may be a site
of mutation following radiation treatment.
The authors would like to thank Dr A. Chan, Mr P. Mitchell and
Ms S. Moss for their helpful comments, Sandra Smith for skilled
assistance and Ms H. Anton for preparing the manuscript. M.R.S. is
an MRC Training Fellow. This work was supported by grants from
the Medical Research Council and the Cancer Research Campaign.
References
BALABAN-MALENBAUM, G., GILBERT, F., NICHOLS, W.W., HILL,
R., SHIELDS, J. & MEADOWS, A.T. (1981). A deleted chromosome
No. 13 in human retinoblastoma cells: relevance to tumori-
genesis. Cancer Genet. Cytogenet., 3, 243.
BENEDICT, W.F., BANERJEE, A., MARK, C. & MURPHREE, A.L.
(1983). Nonrandom chromosomal changes in untreated retino-
blastomas. Cancer Genet. Cytogenet., 10, 311.
BENEDICT, W.F., SRIVATSAN, E.S., MARK, C., BANERJEE, A.,
SPARKES, R.S. & MURPHREE, A.L. (1987). Complete or partial
homozygosity of chromosome 13 in a primary retinoblastoma.
Cancer Res., 47, 4189.
CAPON, D.J., CHEN, E.Y., LEVINSON, A.D., SEEBURG, P. &
GOEDDEL, D.V. (1983). Complete nucleotide sequences of the
T24 human bladder carcinoma oncogene and its normal homo-
logue. Nature, 302, 33.
CAVENEE, W.K., DRYJA, T.P., PHILLIPS, R.A. and 6 others (1983).
Expression of recessive alleles by chromosomal mechanisms in
retinoblastoma. Nature, 305, 779.
COOPER, C.S., BLAIR, D.G., OSKARSSON, M.K., TAINSKY, M.A.,
EADER, L.A. & VANDE WOUDE, G.F. (1984). Characterisation of
human transforming genes from chemically transformed, terato-
carcinoma and pancreatic carcinoma cell lines. Cancer Res., 44,
1.
DERKINDEREN, D.J., KOTEN, J.W., NAGELKERKE, N.J.D., TAN,
K.E.W.P., BEEMER, F.A. & DENOTTER, W. (1988). Non-ocular
cancer in patients with hereditary retinoblastoma and their
relatives. Int. J. Cancer, 41, 499.
DRAPER, G.J., SANDERS, B.M. & KINGSTON, J.E. (1986). Second
primary neoplasms in patients with retinoblastoma. Br. J.
Cancer, 53, 661.
DRYJA, T.P., CAVENEE, W., WHITE, R. and 4 others (1984). Homo-
zygosity of chromosome 13 in retinoblastoma. N. Engl. J. Med.,
310, 550.
DUNN, J.M., PHILLIPS, R.A., BECKER, A.J. & GALLIE, B.L. (1988).
Identification of germline and somatic mutations affecting the
retinoblastoma gene. Science, 241, 1797.
ENZINGER, F.M. & WEISS, S.W. (1988). Soft Tissue Tumors. C.V.
Mosby: St Louis.
FEINBERG, A.P. & VOGELSTEIN, B. (1983). A technique for radio-
labelling DNA restriction endonuclease fragments to high speci-
fic activity. Anal. Biochem., 132, 6.
FRIEND, S.H., BERNARDS, R., ROGELJ, S. and 4 others (1986). A
human DNA segment with properties of the gene that predis-
poses to retinoblastoma and osteosarcoma. Nature, 323, 643.
FRIEND, S.H., HOROWITZ, J.M., GERBER, M.R. and 4 others (1987).
Deletions of a DNA sequence in retinoblastomas and mesen-
chymal tumors: organization of the sequence and its encoded
protein. Proc. Natl Acad. Sci. USA, 84, 9059.
FUNG, Y.-K.T., MURPHREE, A.L., T'ANG, A., QIAN, J., HINRICHS,
S.H. & BENEDICT, W.F. (1987). Structural evidence for the
authenticity of the human retinoblastoma gene. Science, 236,
1657.
GALLIMORE, P.H. & RICHARDSON, P.R. (1973). An improved band-
ing technique exemplified in the karyotype of two strains of rat.
Chromosoma, 41, 259.
GODDARD, A.D., BALAKIER, H., CANTON, M. and 6 others (1988).
Infrequent genomic rearrangement and normal expression of the
putative RB1 gene in retinoblastoma tumors. Mol. Cell Biol., 8,
2082.
HANSEN, M.F., KOUFOS, A., GALLIE, B.L. and 5 others (1985).
Osteosarcoma and retinoblastoma: a shared chromosomal
mechanism revealing recessive predisposition. Proc. Natl Acad.
Sci. USA, 82, 6216.
HARBOUR, J.W., LAI, S.-L., WHANG-PENG, J., GAZDAR, A.F.,
MINNA, J.D. & KAYE, F.J. (1988). Abnormalities in structure and
expression of the human retinoblastoma gene in SCLC. Science,
241, 353.
KNUDSON, A.G. (1971). Mutation and cancer: statistical study of
retinoblastoma. Proc. Natl Acad. Sci. USA, 68, 820.
LEE, W.H., BOOKSTEIN, R., HONG, F., YOUNG, L.J., SHEW, J.Y. &
LEE, E.Y. (1987). Human retinoblastoma susceptibility gene:
cloning, identification, and sequence. Science, 235, 1394.
LEE, Y.-H.P., TO, H., SHEW, J.-Y. BOOKSTEIN, R., SCULLY, P. & LEE,
W.-H. (1988). Inactivation of the retinoblastoma susceptibility
gene in human breast cancers. Science, 241, 218.
SCRABLE, H.J., WITTE, D.P., LAMPKIN, B.C. & CAVENEE, W.K.
(1987). Chromosomal localization of the human rhabdomyo-
sarcoma locus by mitotic recombination mapping. Nature, 329,
645.
T'ANG, A., VARLEY, J.M., CHAKRABORTY, S., MURPHREE, A.L. &
FUNG, Y.-K.T. (1988). Structural rearrangement of the retino-
blastoma gene in human breast carcinoma. Science, 242, 263.
TOGUCHIDA, J., ISHIZAKI, K., SASAKI, M.S. and 4 others (1988).
Chromosomal reorganization for the expression of recessive
mutation of retinoblastoma susceptibility gene in the develop-
ment of osteosarcoma. Cancer Res., 48, 3939.
WIGGS, J., NORDENSKJOLD, M., YANDELL, D. and 11 others
(1988). Prediction of the risk of hereditary retinoblastoma, using
DNA polymorphisms within the retinoblastoma gene. N. Engl. J.
Med., 318, 151.
WONG, Z., WILSON, V., JEFFREYS, A.J. & THEIN, S.L. (1986).
Cloning a selected fragment from a human DNA 'fingerprint':
isolation of an extremely polymorphic minisatellite. Nucleic Acids
Res., 14, 4605.
YUNIS, J.J. & RAMSEY, N. (1978). Retinoblastoma and subband
deletion of chromosome 13. Am. J. Dis. Child., 132, 161.